Skip to content

Financing Cash Flow at other companies

Abbott logo
AbbottABT
$17.31B+942%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$1.09B+1,172%
Danaher logo
DanaherDHR
$46M+104%
Agilent Technologies logo
Agilent TechnologiesA
-$144M-24.1%
Revvity logo
RevvityRVTY
-$88.9M+45.7%
Labcorp Holdings logo
Labcorp HoldingsLH
$580.5M+169%

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s financing cash flow?
Bio-Rad Laboratories, Inc. (BIO.B) reported financing cash flow of -$44M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s financing cash flow changed year-over-year?
Bio-Rad Laboratories, Inc.'s financing cash flow increased by 55.0% year-over-year, from -$97.7M to -$44M.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s financing cash flow?
Over 2 years (2023 to 2025), Bio-Rad Laboratories, Inc.'s financing cash flow has grown at a -18.0% compound annual growth rate (CAGR), from -$425.6M to -$286.5M.